Theravance Biopharma shares owned by Ubs Global Asset Management Americas
Quarter-by-quarter ownership of Theravance Biopharma (TBPH) shares owned by Ubs Global Asset Management Americas
from 13F filings
Historical chart of Ubs Global Asset Management Americas investment in Theravance Biopharma
Tip: Access up to 7 years of quarterly data
All positions including Theravance Biopharma held by Ubs Global Asset Management Americas consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelQuarterly reported holdings in Theravance Biopharma by Ubs Global Asset Management Americas
Quarter filed | Position value | Share count | Share price at filing |
---|---|---|---|
2023-12-31 | $725k | 65k | 11.24 |
2023-09-30 | $530k | 61k | 8.63 |
2023-06-30 | $666k | 61k | 10.85 |
2023-03-31 | $666k | 61k | 10.85 |
2022-12-31 | $730k | 65k | 11.22 |
2022-09-30 | $734k | 72k | 10.14 |
2022-06-30 | $656k | 72k | 9.06 |
2022-03-31 | $715k | 75k | 9.56 |
2021-12-31 | $819k | 74k | 11.05 |
2021-09-30 | $477k | 65k | 7.40 |
2021-06-30 | $928k | 64k | 14.52 |
2021-03-31 | $1.2M | 61k | 20.41 |
2020-12-31 | $642k | 43k | 14.79 |
2020-09-30 | $642k | 43k | 14.79 |
2020-06-30 | $912k | 43k | 20.99 |
2020-03-31 | $781k | 34k | 23.11 |
2019-12-31 | $874k | 34k | 25.89 |
2019-09-30 | $523k | 27k | 19.48 |
2019-06-30 | $214k | 13k | 16.33 |
2019-03-31 | $298k | 13k | 22.67 |
2018-12-31 | $521k | 20k | 25.59 |
2018-09-30 | $564k | 17k | 32.67 |
2018-06-30 | $207k | 9.1k | 22.68 |
2018-03-31 | $221k | 9.1k | 24.25 |
2017-12-31 | $476k | 17k | 27.89 |
2017-09-30 | $822k | 24k | 34.24 |
2017-06-30 | $830k | 21k | 39.84 |
2017-03-31 | $247k | 6.7k | 36.82 |
2016-12-31 | $214k | 6.7k | 31.85 |
2016-09-30 | $436k | 12k | 36.28 |
2016-06-30 | $273k | 12k | 22.71 |
2015-03-31 | $8.2M | 472k | 17.35 |
2014-12-31 | $3.5M | 234k | 14.92 |
2014-09-30 | $5.3M | 231k | 23.05 |
2014-06-30 | $7.0M | 221k | 31.88 |
More positions owned by Ubs Global Asset Management Americas
View all positions for Ubs Global Asset Management Americas